louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03507426: Retrobulbar Block Versus Ketamine Infusion for Post-enucleation Analgesia
Official title: Retrobulbar Block Versus Ketamine Infusion as Adjuvants to General Anesthesia for Post-operative Pain Control After Enucleation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Enucleated; Eye
Evisceration; Operation Wound
Pain, Postoperative
Keywords: Retrobulbar block
Ketamine
Ocular enucleation
Analgesia
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-04-25
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study compares the efficacy and safety of two techniques, retrobulbar block versus intra-operative ketamine infusion, for control of post-operative pain occurring in patients undergoing ocular enucleation or evisceration performed under general anesthesia.


Eligibility criteria: Inclusion Criteria:

* Ocular enucleation candidate patients
* Ocular evisceration candidate patients

Exclusion Criteria:

* Any condition contra-indicating general or local anesthesia
* Allergy to any of the drugs used during the procedure

Primary outcomes:
measure: Time to the first post-operative rescue analgesia.
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Al-Ainy Hospital, Cairo University
Study officials:
affiliation: Kasr Al-Ainy Hospital, Cairo University
name: Ahmed M El-Badawy, MD
role: STUDY_CHAIR
affiliation: Kasr Al-Ainy Hospital, Cairo University
name: Nazmy E Seif, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01019226: Implementation of Work in Progress (WIP) Sequences in Magnetic Resonance Imaging (MRI)
Official title: Implementation of Work in Progress (WIP) Sequences in MRI
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Cardiomyopathy
Nonischemic Cardiomyopathy
Keywords: myocardium
Magnetic resonance imaging
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2009-11-25
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing cardiac MRI

Brief summary: Trial of new work in progress (WIP) sequences in MRI.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of ischemic or non ischemic cardiomyopathy

Exclusion Criteria:

* claustrophobia
* irregular heart rhythm

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Hashomer
country: Israel
facility: Sheba medical center
Study officials:
affiliation: Sheba Medical Center
name: Eli Konen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00556426: Prospective, Multi-center, Single-arm Study to Assess the Safety of Retrieval of the Recovery G2 Filter.
Official title: The Bard® Recovery® Filter Registry (EVEREST) for Patients Who Are Candidates for an Optional (Retrievable) Inferior Vena Cava Filter That Undergo Placement of the Bard® Recovery® Filter.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulmonary Embolism
Venous Thromboembolic Disease
Keywords: Venous Thromboembolic Disease
IVC Filter
Pulmonary Embolism
Lead sponsor: C. R. Bard
Sponsor class: INDUSTRY
First posted: 2007-11-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study was designed to assess the safety of retrieval of the Bard Recovery® G2® Filter System. The G2 filter is an FDA-cleared device for inferior vena caval interruption in patients with pulmonary thromboembolism.


Eligibility criteria: Inclusion Criteria:

* The patient is at temporary , increased risk of pulmonary embolism requiring caval interruption

Exclusion Criteria:

* The patient has implanted filter in the IVC or superior vena cava (SVC)
* The patient has a duplicated or left-sided IVC
* The patient has a known untreatable or uncontrollable malignancy
* The patient has severe spinal deformity
* The patient has a creatinine \> 2.0 mg/dl
* The patient has a life expectancy of \< 6 months

Primary outcomes:
measure: Technical Success (Retrieval)
timeFrame: 1 month post filter retrieval or through 6 months following implantation
measure: Clinical Success (Retrieval)
timeFrame: Time of Retrieval or through 6 months of implantation
measure: Percentage of Participants With Adverse Events Through 30 Days Post Retrieval
timeFrame: 30 days post retrieval
Secondary outcomes:
measure: Filter Migration > 2cm
timeFrame: 30 days post retrieval or 6 months following filter placement
measure: Incidence of Filter Fracture
timeFrame: at 6 months or at retrieval of the filter
Other outcomes:
Locations:
Study officials:
affiliation: OHSU, Portland, Oregon
name: John A Kaufman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05302726: Impact of Exogenous Estrogens on Cotisol Levels During Synacthen Stimulation
Official title: Betydning af Eksogent østrogen på Serum Kortisol Under Synacthen-stimulering Hos Hypogonade Kvinder Med Binyrebarkinsufficiens
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Adrenal Insufficiency
Hypogonadism Female
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2022-03-31
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: All patients will be examinated after 3 months on oral estrogen, 3 months on transdermal estrogen and after 3 months without estrogen substitution
Primary purpose: DIAGNOSTIC

Brief summary: The aim is to investigate impact of exogenous estrogens on cotisol Levels during synacthen stimulation in female hypogonal patients on estrogen substitution. Both patients with and withour adrenal insufficiency will be studied

Detailed description: The aim is to investigate impact of exogenous estrogens on cotisol levels during synacthen stimulation in female hypogonal patients on estrogen substitution. Both patients with and without adrenal insufficiency will be studied . All patients (inclusion criteria age 18-50 years, BMI \<35) will be followed for 6 months and have 3 synacthentests performed: One on transdermal estrogen (minimum 3 months), one on oral estrogens (min 3 months) and one without estrogen substitution for at least 3 months. Primary endpoint is change in serum cortisol 30 minutes after synacthen stimulation

Eligibility criteria: Inclusion Criteria:

* Hypogonadism
* Treatment with estrogen substitution

Exclusion Criteria:

* Other formulations of glucocorticoid than oral hydrocortisone
* Pregnancy
* BMI \> 35

Primary outcomes:
measure: Change in serum cortisol oral estrogen
timeFrame: Assessment will take place before and 3 months after introduction of the intervention
measure: Change in serum cortisol transdermal estrogen
timeFrame: Assessment will take place before and 3 months after introduction of the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Mikkel Mr Andreassen
Study officials:
affiliation: Department of endocrinology and metabolism
name: Mikkel M Andreassen
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05850026: Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Official title: Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertrophic Obstructive Cardiomyopathy
Mitral Regurgitation
Lead sponsor: Ospedale San Raffaele
Sponsor class: OTHER
First posted: 2023-05-09
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with HOCM and MR, who underwent concomitant septal myectomy and mitral valve repair with edge-to-edge technique

Brief summary: Septal myectomy is performed in selected cases to treat patients with hypertrophic obstructive cardiomyopathy (HOCM). The mechanism that causes obstruction involves both the outflow tract itself and the mitral apparatus, with the appearance of mitral regurgitation (MR) by SAM (Systolic Anterior Motion).

When the interventricular septum is not particularly thick, isolated myectomy may not be sufficient to eliminate the SAM; in these cases the concomitant treatment of the mitral valve is considered. Different approaches have been proposed: mitral replacement with prosthesis, plication or lengthening of the anterior leaflet or the edge-to-edge (EE) technique.

In addition, a small proportion of patients with HOCM may have MR from organic valve abnormalities, requiring specific treatment.

Currently, there are few studies in the literature aimed at determining the role of EE in the context of HOCM; most of these studies are characterized by short follow-up or by the scarcity of echocardiographic data.

The aim of the present study is to evaluate the long-term outcomes of EE associated with septal myectomy in patients with CMIO, both from a clinical point of view and by reporting echocardiographic data.


Eligibility criteria: Inclusion Criteria:

* diagnosis of HOCM with indication for surgery,
* patients operated on from 2000 to 2017
* contextual diagnosis of MR needing reparative surgical treatment
* age ≥ 18 years

Exclusion Criteria:

* hypertophic left ventricle due to other causes (aortic stenosis, arterial hypertension)

Primary outcomes:
measure: Survival time after intervention
timeFrame: through study completion, a minimum of 2 years
measure: freedom from reintervention
timeFrame: through study completion, a minimum of 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: IRCCS Ospedale San Raffaele
Study officials:
References:
Clinical trial NCT01560026: Retrospective Study to Evaluate the Feasibility of Ovarian Preservation in Patients With Endometrial Carcinoma
Official title: Study for Elevate the Feasibility of Ovarian Preservation With Endometrial Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Endometrial Cancer
Keywords: ovarian preservation
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2012-03-21
Enrollment: 300
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The investigators retrospectively reviewed the cases of 150 patients who had primary surgery with early stage endometrial cancer between January 1989 and December 2009

Brief summary: Endometrial cancer is one of the most common female malignancies in the United States, and has increased in incidence in Taiwan in recent decades.A recent population-based analysis noted that 4% of endometrial cancers occurred in women aged 40 years or younger, furthermore it is up to 15% in Taiwan according to the data of cancer registry. The standard treatment of endometrial cancer results in surgical menopause and places patients at risk for the long-term sequelae of estrogen deprivation. The goal of this study was to determine the frequency of a coexisting ovarian malignancy and to evaluate the outcome of ovarian preservation in women with treatment for endometrial cancer.

Detailed description: we reviewed the cases with early stage of endometrial cancer who have primary staging surgery between January 1989 to December 2009. The enrolled patients will be divided into two group (oophorectomy vs. ovary preservation) for analysis:the outcome and recurrence type.To evaluate the outcome of ovarian preservation in women with endometrial cancer .

Eligibility criteria: Inclusion Criteria:

* early stage endometrial cancer after primary surgery exclusion criteria:
* MMMT, type 2 endometrial cancer

Primary outcomes:
measure: from the time of diagnosis to the time of disease recurrence or last follow time
timeFrame: disease recurrence or last follow time, up to one year
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
state: ROC
Study officials:
affiliation: Department of Obstetric and Gynecology, Taipei Veterans General Hospital
name: Yi-Jen Chen
role: STUDY_CHAIR
References:
Clinical trial NCT01042626: Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
Official title: Dissimilar PTH, Gastrin, and Ionized Calcium Response to Oral Peptones in Normocalcemic Primary Hyperparathyroidism, Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hyperparathyroidism
Hypercalcemia
Keywords: Receptors, Calcium sensing
Parathyroid Hormone
Lead sponsor: University of Eastern Piedmont
Sponsor class: OTHER
Collaborators: name: University of Milan
First posted: 2010-01-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to assess if subjects with hyperparathyroidism with normal serum calcium levels have different responses in the calcium regulating hormonal handling compared to a) patients with primary hyperparathyroidism and high serum calcium levels; b) healthy subjects.

The differences will be evaluated with oral peptones load and subsequent blood samples collected every 15 minutes for two hours. Ionized calcium, phosphate, gastrin and PTH levels will be evaluated.


Eligibility criteria: Inclusion Criteria:

1. normocalcemic hyperparathyroidism

   * presence of high serum levels of intact PTH
   * serum ionized calcium levels in the high normality range
2. hypercalcemic hyperparathyroidism

   * presence of high serum levels of intact PTH
   * high serum ionized calcium levels

Exclusion Criteria:

1. potential causes of secondary hyperparathyroidism like renal insufficiency, liver disease, malabsorption, hypercalciuria, Paget's disease, thiazide diuretic or lithium use.
2. bone disease of any origin

Primary outcomes:
measure: PTH levels variations
timeFrame: 2 hours
measure: Ionized serum calcium variations
timeFrame: 2 hours
measure: Serum phosphate variations
timeFrame: 2 hours
measure: Serum gastrin variations
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: L. Sacco Hospital (Vialba)
state: MI
Study officials:
References:
citation: Bevilacqua M, Dominguez LJ, Righini V, Valdes V, Vago T, Leopaldi E, Baldi G, Barrella M, Barbagallo M. Dissimilar PTH, gastrin, and calcitonin responses to oral calcium and peptones in hypocalciuric hypercalcemia, primary hyperparathyroidism, and normal subjects: a useful tool for differential diagnosis. J Bone Miner Res. 2006 Mar;21(3):406-12. doi: 10.1359/JBMR.051210. Epub 2005 Dec 19.
Clinical trial NCT02260726: Evaluation of Ultrasound for Detecting Hip Impingement
Official title: Diagnosing Deformities of the Hip Associated With Arthritis: MRI vs Ultrasound
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Femoroacetabular Impingement
Keywords: femoroacetabular impingement
morphometry
dynamic
magnetic resonance imaging
ultrasound
screening
diagnosis
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2014-10-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: Patients are being asked to participate in this study because a previous research MRI of their hips showed that the shape of the head of their thigh bone may indicate FAI of the hip. We have already collected cartilage imaging data and data on how the hip joint moves on people with painful/symptomatic FAI and people with normal hip function. We would now like to compare the motion of the hip joint to those with painful FAI using ultrasound.

Detailed description: Hip impingement is thought to be a leading cause of hip osteoarthritis, and occurs due to deformities in the hip joint. However some individuals have these deformities but do not exhibit symptoms. Using the standard magnetic resonance imaging and clinical tests it is not clear which deformities will cause degeneration, requiring surgical intervention. We propose to evaluate the deformity and impingement between the femur and acetabulum using dynamic ultrasound imaging. Ultrasound does not involve radiation and can acquire video of the hip joint and is thus suitable for such diagnostic purposes. In this pilot study we will evaluate the feasibility of ultrasound in diagnosing hip impingement.

Eligibility criteria: Inclusion Criteria:

Surgical group:

* Hip pain longer than 6 months referred to the groin/lateral aspect of the hip
* Positive Impingement Sign

Plain radiographs:

* Absence of arthritis (Tonnis Grade 0 or 1)
* Absence of dysplasia (center edge \>25 degrees) on anterior-posterior radiograph
* α-angle greater than 60 degrees on MRI.

Exclusion Criteria:

* Patients who don't meet inclusion criteria
* Control group: subjects with hip pain or with alpha angle \> 50 degrees on MRI

Primary outcomes:
measure: Ultrasound grade
timeFrame: Upon enrollment
Secondary outcomes:
measure: Ultrasound parameters
timeFrame: Upon enrollment
measure: MRI parameters
timeFrame: Upon enrollment
Other outcomes:
Locations:
Study officials:
affiliation: University of Ottawa / The Ottawa Hospital
name: Paul E Beaule, MD, FRCSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01587326: The Effects of Escitalopram on Cytokines
Official title: The Effects of Escitalopram on Cytokines in Depressive Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Depression
Keywords: cytokine, depression, escitalopram
Lead sponsor: Beitou Armed Forces Hospital, Taipei, Taiwan
Sponsor class: OTHER_GOV
First posted: 2012-04-30
Enrollment: 25
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The association of cytokines with escitalopram has not been investigated in patients with major depressive disorder (MDD). Hence, the investigators will examine this association.

Detailed description: In addition to serotonin, inflammatory process has been suggested in the development of major depressive disorder (MDD) and in its associated treatment. Escitalopram is an antidepressant that has been widely used in patients with MDD because of the promising results. The association of cytokines with escitalopram has not been investigated in patients with MDD. Hence, the investigators will examine this association.

Eligibility criteria: Inclusion Criteria:

1. DSM-IV-defined Major depressive disorder, single episode
2. Age 20-65
3. Drug-naive
4. Hamilton Depression Rating Scale exceeding 14 scores

Exclusion Criteria:

1. Major medical disorders
2. Substance use
3. Pregnant
4. Allergy to escitalopram

Primary outcomes:
measure: The changes in cytokines
timeFrame: Week 0, Week 4
Secondary outcomes:
measure: The changes in Hamilton Depression Rating Scale
timeFrame: week 0, week 4
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Beitou Armed Forces Hospital
Study officials:
affiliation: Beitou Armed Forces Hospital
name: Peishen Ho, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04880226: A Study to Evaluate Non-significant Risk Operation Magnetic Resonance Imaging for MRI Guided Ablation
Official title: Evaluation of Non Significant Risk Operation Magnetic Resonance Imaging for MR Guided Ablation Using the Philips MRI
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Keywords: MRI-guided biopsy and/or ablation procedure
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-05-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The result of these studies will be used to improve patient care through assessment of new technology to determine whether it is beneficial (i.e. improving data acquisition speed or image quality) during iMRI procedures.

Detailed description: This proposal includes evaluation of advanced MR imaging methods in the iMRI environment and will operate within the NSR guidelines for data acquisition established by the FDA/CDRH. The significant testing by vendor and Mayo staff prior to in vivo use, assure the safety of these studies and overall system stability.

The result of these studies will be used to improve patient care through assessment of new technology to determine whether it is beneficial (i.e. improving data acquisition speed or image quality) during iMRI procedures.

Eligibility criteria: Inclusion Criteria:

* Male or female.
* Age ≥ 18 years.
* Healthy volunteers or patients already scheduled for a MR-guided procedure.

Exclusion Criteria:

* Individuals 18 years of age.
* Pregnant women.

Primary outcomes:
measure: Clinical determination whether the sequence improves patient care during MRI-guided procedures.
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Aiming Lu, PhD
role: PRINCIPAL_INVESTIGATOR
References: